Decreased risk of breast cancer associated with oral bisphosphonate therapy
Aju Mathew,1 Adam Brufsky,21Department of Internal Medicine, University of Pittsburgh Medical Center, 2Division of Hematology/Oncology, Magee-Womens Hospital, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USAAbstract: Preclinical studies and adjuvant trials using bisphosphonates have fo...
Enregistré dans:
Auteurs principaux: | Mathew A, Brufsky A |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2012
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/7ba30ee2c0064d89a8d91a7226d0fe49 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer
par: Bauer M, et autres
Publié: (2012) -
Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer
par: Allan Lipton
Publié: (2011) -
Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer
par: Brock Schroeder, et autres
Publié: (2017) -
Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ
par: Mathilde M. M. Almekinders, et autres
Publié: (2021) -
Does Adjunctive Naturopathic Care Decrease Survival Rates in Breast Cancer Patients?
par: Keith I. Block MD
Publié: (2021)